Investigational drug · Phase 3
Amlitelimab
Also called: SAR445229
Not approved by FDA. In 9 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Dermatitis Atopic, Coeliac Disease, Celiac Disease.
Phase 3Last checked: Nov 19, 2026Latest source record: Oct 13, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
9
5 still active
All registered trials
17
Any phase or sponsor naming "Amlitelimab"
First trial start
2022
Aug 22, 2022
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Amlitelimab", any sponsor or status.
- Phase 210
Conditions studied
As listed on its trial records.
- Dermatitis Atopic
- Coeliac Disease
- Celiac Disease
Approved drugs for the same conditions: Gastroenterology and liver · Dermatology
Largest trials
Live from ClinicalTrials.gov: studies naming "Amlitelimab" as an intervention, largest first.
- Long-Term Safety and Efficacy Evaluation of Amlitelimab in Participants of Previous Amlitelimab Moderate to Severe Atopic Dermatitis Clinical TrialsPivotal-lookingActive, not recruiting
SanofiSanofi (SNY)
NCT05492578 · 1,856 participants · Start Aug 22, 2022 · Primary completion Jan 22, 2029
Drug: Amlitelimab; Topical corticosteroids and 2 more · For: Dermatitis Atopic
Sites: Birmingham, Alabama; Scottsdale, Arizona; Tucson, Arizona · 392 sites in all
- A Study to Evaluate the Treatment Response and Safety of Two Dose Regimens of Subcutaneous Amlitelimab Compared With Treatment Withdrawal in Participants Aged 12 Years and Older With Moderate-to-severe Atopic DermatitisPivotal-lookingActive, not recruiting
SanofiSanofi (SNY)
NCT06407934 · 1,541 participants · Start May 8, 2024 · Primary completion Jun 10, 2026
Drug: Amlitelimab; Placebo · For: Dermatitis Atopic
Sites: Birmingham, Alabama; Scottsdale, Arizona; Tucson, Arizona · 324 sites in all
- Open Label, Long-term Study Evaluating Safety and Efficacy of Subcutaneous Amlitelimab in Participants Aged 12 Years and Older With Moderate to Severe Atopic DermatitisActive, not recruiting
SanofiSanofi (SNY)
NCT05769777 · 999 participants · Start Apr 3, 2023 · Primary completion Jun 11, 2031
Drug: Amlitelimab · For: Dermatitis Atopic
Sites: Birmingham, Alabama; Litchfield Park, Arizona; Bryant, Arkansas · 174 sites in all
- A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis on Background Topical CorticosteroidsPivotal-lookingCompleted
SanofiSanofi (SNY)
NCT06224348 · 643 participants · Start Jan 18, 2024 · Primary completion Aug 21, 2025
Drug: Amlitelimab; Placebo and 2 more · For: Dermatitis Atopic
Sites: Birmingham, Alabama; Fort Smith, Arkansas; Encino, California · 167 sites in all
- A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab Monotherapy Compared With Placebo in Participants Aged 12 Years and Older With Moderate-to-severe Atopic DermatitisPivotal-lookingCompleted
SanofiSanofi (SNY)
NCT06130566 · 601 participants · Start Nov 8, 2023 · Primary completion Jul 23, 2025
Drug: Amlitelimab; Placebo · For: Dermatitis Atopic
Sites: Scottsdale, Arizona; Fountain Valley, California; Fremont, California · 148 sites in all
- A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab Monotherapy Compared With Placebo in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis (COAST 2)Pivotal-lookingCompleted
SanofiSanofi (SNY)
NCT06181435 · 589 participants · Start Dec 21, 2023 · Primary completion Nov 25, 2025
Drug: Amlitelimab; Placebo · For: Dermatitis Atopic
Sites: Scottsdale, Arizona; Tucson, Arizona; Lomita, California · 142 sites in all
- A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab on Background Topical Corticosteroids Therapy in Participants Aged 12 Years and Older With Moderate-to-severe AD Who Have Had an Inadequate Response to Prior Biologic Therapy or an Oral JAK InhibitorPivotal-lookingActive, not recruiting
SanofiSanofi (SNY)
NCT06241118 · 464 participants · Start Feb 29, 2024 · Primary completion Sep 30, 2027
Drug: Amlitelimab; Placebo and 2 more · For: Dermatitis Atopic
Sites: Birmingham, Alabama; Scottsdale, Arizona; North Little Rock, Arkansas · 154 sites in all
- Dose Ranging Study of Amlitelimab in Adult Participants With Moderate-to-severe AsthmaPivotal-lookingCompleted
SanofiSanofi (SNY)
NCT05421598 · 437 participants · Start Jun 30, 2022 · Primary completion Oct 11, 2024
Drug: Amlitelimab; Placebo · For: Asthma
Sites: La Jolla, California; Los Angeles, California; San Jose, California · 113 sites in all
- Platform Clinical Study for Conquering SclerodermaPivotal-lookingRecruiting
Scleroderma Research Foundation, Inc.Academic, hospital or other
NCT06195072 · 400 participants (planned) · Start Apr 15, 2024 · Primary completion Nov 2026
Drug: Amlitelimab; BI 1015550 (Nerandomilast) and 1 more · For: Interstitial Lung Disease Due to Systemic Disease; Scleroderma
Sites: Birmingham, Alabama; Los Angeles, California; Palo Alto, California · 34 sites in all
- Study Testing Response Effect of KY1005 Against Moderate-to-Severe Atopic Dermatitis, The STREAM-AD StudyPivotal-lookingCompleted
Kymab LimitedIndustry
NCT05131477 · 390 participants · Start Dec 13, 2021 · Primary completion Apr 26, 2023
Drug: Amlitelimab; Placebo · For: Eczema; Atopic Dermatitis
Sites: Fremont, California; Sacramento, California; Boca Raton, Florida · 103 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- OX40/OX40L modulation: A target for regulating T cells in cutaneous inflammatory disorders.
Gupta AK, Steriopoulos J, Economopoulos V, et al. · J Eur Acad Dermatol Venereol 2026
- Molecular differentiation of OX40- and OX40L-targeted biologics using AlphaFold3 and molecular dynamics simulations.
Nolden K, Shi Y, Batista VS, et al. · J Invest Dermatol 2026
- The OX40-OX40L Co-Stimulatory Pathway as a Shared Driver of Immune Persistence in Skin and Airway Inflammation.
Navarro-Triviño FJ, Torres T, Ruiz-Villaverde R, et al. · Clin Rev Allergy Immunol 2026
- Is Kaposi's sarcoma the end of the OX40/OX40L axis in atopic dermatitis?
Salek-Ardakani S · Front Immunol 2026
- Disproportionate quality of life decline and unaddressed limitations in amlitelimab atopic dermatitis trial.
Chen SC, Ting TL · J Eur Acad Dermatol Venereol 2026
- Biologic Monotherapies for Moderate-to-Severe Atopic Dermatitis: A Systematic Review and Bayesian Network Meta-Analysis of Established and Investigational Agents.
Babul A, Mehta D, Soliman Y, et al. · Cureus 2026
Also in development for Dermatitis Atopic
- LunsekimigSAR443765Phase 39 trials
Sanofi · Asthma, Chronic Obstructive Pulmonary Disease, Chronic Rhinosinusitis With Nasal Polyps
- calcineurin inhibitorsPhase 32 trials
Sanofi · Dermatitis Atopic
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Sanofi.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.